mr square mark

Margaret Patrick

Margaret Patrick joined Market Realist in September 2014 and has written close to 3,000 articles. She has covered the healthcare sector, which includes pharmaceutical and biotechnology companies, medical device companies, health insurance companies, and hospital companies. Currently, she is following the cannabis sector.

Prior to joining Market Realist, Margaret worked as equity and data analyst at MSCI for a year and as a financial research analyst at Deloitte for two years. She completed her MBA with finance specialization in 2011. She also passed all three CFA levels.

Besides writing on stocks, Margaret loves to read about nutrition, culture, and mythology. She's also fond of traveling to new places.

Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.

More From Margaret Patrick

  • How Does Aetna Compare to Its Peers in Medical Care Ratio?
    Company & Industry Overviews

    How Does Aetna Compare to Its Peers in Medical Care Ratio?

    The medical care ratio of health insurance companies is calculated as the ratio of the total money spent in health care claims to premiums earned.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Teva Can Benefit by Acquiring Allergan Generics

    The combined Teva–Allergan generics entity should have approximately 320 Abbreviated New Drug Applications (or ANDAs), including 110 first-to-file ANDAs (or FTF) in the US.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for United Therapeutics

    In 2Q17, United Therapeutics (UTHR) reported revenue of ~$445 million, representing year-over-year growth of around 8%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Merck Expects Modest Revenue Growth in Fiscal 2016

    Merck provided revenue guidance of $39.7 billion–$40.2 billion in 2016. It expects negative foreign exchange fluctuations to reduce its fiscal 2016 revenue.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Biogen’s Experimental Alzheimer Therapy: Limited 2Q15 Success

    On July 22, 2015, Biogen (BIIB) released data from a Phase 1b study, also called the PRIME Study, that looked at the effectiveness of its investigational Alzheimer’s drug, BIIB037.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Analysts’ Recommendations for Merck in 2017?

    For 2016, Merck & Co. (MRK) reported revenue close to $39.8 billion, a year-over-year (or YoY) rise of ~1%. New product launches have played major roles in boosting Merck’s 2016 revenue.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Restricted Access Continues to Impact Praluent Sales in 2016

    Praluent is one of the Regeneron’s key new additions in the cardiovascular segment. It’s a PCSK9 therapy approved for lowering LDL cholesterol in patients.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Think about Bristol-Myers Squibb

    Of 28 analysts covering BMY’s stock, 42.3% gave it a “buy” recommendation, while 50.0% gave it a “hold” recommendation. Only 7.7% rated it as a “sell.”

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Analysts’ Recommendations for Anthem in 2017

    Based on the company’s performance in 1Q17, Anthem (ANTM) has increased its 2017 revenue guidance by around $1.5 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Celgene’s Revlimid Expected to Post Strong Revenue in 2017

    According to unaudited financial results published by Celgene (CELG) on January 9, 2017, Revlimid sales for 2016 are about $7.0 billion, a YoY rise of about 20.0%.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    What’s UnitedHealth Group’s outlook for 2015?

    It’s projected that UnitedHealth Group’s revenue and earnings growth in 2015 will be driven by the strong performance of the Optum segments.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    How Gilead Sciences’ Gross Margin Outshines Its Peers

    Despite a year-over-year (or YoY) drop in revenues in 2Q16, Gilead Sciences (GILD) managed to earn gross margins of about 92%.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Enrollments decreased in UnitedHealth’s international business

    In the US, the private health insurance industry has been expanding its footprint in international markets. International markets are less penetrated and competitive.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Teva Pharmaceutical in 2017

    Following the completion of its acquisition of Allergan’s Actavis Generics business on August 2, 2016, Teva Pharmaceutical plans to focus on realizing the deal’s synergies in 2017.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    UnitedHealth Group’s Optum segment: Earnings rose in 2014

    UnitedHealth Group (UNH) operates Optum. It provides health services like health technology, health and well-being, and pharmacy services.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analyzing Pfizer’s Expense Projections for 2018

    Pfizer expects its 2018 R&D (research and development) expenses to be in the range of $7.7 billion–$8.1 billion.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Amgen Continues to Control Operating Expenses in 3Q15

    In 3Q15, Amgen recorded total operating expenses of ~$3.4 billion. This fall in expenses enabled the company to report a net profit margin of ~36.4%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alexion Pharmaceuticals Adds Metabolic Drug Kanuma to Portfolio

    Kanuma was acquired by Alexion Pharmaceuticals on completion of the acquisition of Synageva Pharmaceuticals in June 2015.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Label Expansion Expected to Boost Keytruda’s 2017 Revenue

    On October 24, 2016, the FDA approved Merck & Co’s (MRK) Keytruda as a second-line therapy for patients suffering from non-small cell lung cancer (or NSCLC).

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Humana’s core business: The Medicare Advantage program

    Humana’s total enrollment is mainly enrollments in the MA program, a substitute for the original Medicare program, via private insurance companies.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Bristol-Myer Squibb’s Opdivo Is Keytruda’s Strong Competitor

    the U.S. Food and Drug Administration accepted the filing of a supplemental Biologics License Application for Bristol-Myers Squibb’s Opdivo.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Must-Read: Amgen’s 3Q15 Earnings and Conference Call

    In its 3Q15 earnings report released on October 28, Amgen reported YoY revenue growth of ~14.0%, from $5.0 billion in 3Q14 to $5.7 billion in 3Q15.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Amgen Continues to Be Confident in Repatha in 2017

    In 1Q17, Amgen’s (AMGN) PCSK9 inhibitor therapy, Repatha, reported revenue of nearly $49 million. The drug earned $33 million in revenue in US markets and $16 million in international revenue.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Could Expand Keytruda’s Revenues?

    In addition to the US market, Merck’s (MRK) Keytruda has been approved in more than 50 international markets for metastatic melanoma.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    How Biogen’s Tysabri and Zinbryta Performed in 1Q17

    In 1Q17, Biogen (BIIB) saw an increased demand for Tysabri, both in the United States and in international markets.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Venclexta Witnessed Healthy Demand Trends in 1Q17

    AbbVie’s (ABBV) Venclexta was approved by the FDA on April 11, 2016. AbbVie has also successfully launched Venclexta in Germany and France.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Inside Celgene’s Revlimid: Strong Patient Demand in 4Q16

    After the approval of the drug as a therapy for newly diagnosed multiple myeloma, Celgene’s Revlimid has witnessed rapid growth in market share worldwide.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Analysts Expect Biogen’s Net Profit Margins to Rise in 3Q15

    Biogen’s (BIIB) 3Q15 earnings results will be announced on October 21, 2015. Analysts expect that the company will report lower net profit margins as compared to 2Q15.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Why UnitedHealth Group Plans to Reduce Its Public Exchange Exposure

    Given the high-risk profile of individual exchange enrollments, UnitedHealth Group has decided to offer plans only on a few public exchanges in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Valeant’s Dermatology Business Felt Pricing Pressure in 2016

    Dermatology pricing trends Valeant Pharmaceuticals’ (VRX) dermatology business witnessed intense pricing pressure in 2016, due to a change in the company’s distribution model in 4Q15. While Valeant previously marketed its dermatology drugs through specialty pharmacies, the company now distributes its products through Walgreens. To learn about the company’s current distribution model, please refer to How Valeant Plans […]

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Behind Amgen’s Plans to Penetrate the Migraine Segment

    Amgen and Novartis are exploring an investigational drug that is a CGRP antibody, AMG 334, for the treatment of episodic and chronic migraine headaches.

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    Aurora Cannabis’s Price Target Cut by 30%

    Aurora Cannabis (ACB) stock is currently down 29.23% on the NYSE on a YTD (year-to-date) basis. The company has lost 14.81% of its value since October 1.

    By Margaret Patrick
  • uploads///Graph
    Macroeconomic Analysis

    Assessing the economy’s impact on national healthcare spending

    National healthcare spending is a major driver of the hospital industry. National spending on hospital care is expected to amount to $973 million.

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    The Pet Cannabis Industry Is a Lucrative Opportunity

    Spending on pet care is gradually rising in the US. As reported by CNBC, Nielsen estimated Americans spent $33 billion on pet food and treats last year.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Siliq May be a Strong Growth Driver for Valeant in 2017

    Siliq growth trends On February 15, 2017, the FDA approved injectable biologic therapy Siliq (brodalumab) as a treatment option for moderate-to-severe plaque psoriasis patients. Siliq is for psoriasis patients eligible for systemic therapy or phototherapy, and are not responding sufficiently or have stopped responding to these treatment options. To learn more about Siliq, please refer to What Are […]

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    Marijuana to Treat New Conditions in Minnesota

    In August 2020, chronic pain and age-related macular degeneration would be eligible for treatment under Minnesota’s medical marijuana program.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    AbbVie’s Viekira Pak Saw Weaker-than-Expected Performance

    Viekira Pak managed to earn revenues worth about $414 million in 1Q16. The drug’s sales in the US market, however, fell YoY (year-over-year) by about 9.3% and reached $125 million in 1Q16.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Universal Health Services’ Behavioral Health Business in 3Q15

    Universal Health Services (UHS) is expected to benefit from its leading market position in the behavioral health business in 3Q15.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    International Segment: Key Driver of VRX’s Revenue Growth in 2016

    In the first nine months of 2016, the Bausch + Lomb/International segment reported revenues of ~$3.4 billion, which equals year-over-year (or YoY) growth of ~0.4%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Eylea Could Face Tough Competition in 2016

    In 2016, Regeneron expects to face increased competition from Roche Holding’s Lucentis (Ranibizumab) and Avastin (Bevacizumab) for Eylea.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Emerging Markets Drive Abbott’s Nutritional Business Growth

    In 1Q17, Abbott Laboratories’ (ABT) Nutritional segment reported revenue of nearly $1.6 billion, a year-over-year (or YoY) fall of ~1%.

    By Margaret Patrick
  • uploads///thumbs up _
    Company & Industry Overviews

    Merck Beat Consensus Revenue and EPS Estimates in Q4

    In the fourth quarter, Merck reported total revenues of $11.0 billion—a rise of 5% YoY (year-over-year) on a reported basis.

    By Margaret Patrick
  • uploads///euro _
    Company & Industry Overviews

    Why Amarin Is Soaring in First Half of January

    Amarin has been rising on rumors about pharmaceutical giant Pfizer (PFE) being interested in acquiring the company.

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    An Overview of Canopy Growth and Its Brands

    Canopy Growth (CGC) announced the US launch of First & Free, its hemp-derived CBD product line. CGC offers softgels, oil drops, and creams.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Strong Growth Projected for UTHR’s Hypertension Drugs

    United Therapeutics has projected that in 2016, its trepostinil pulmonary arterial hypertension drugs will benefit from patients’ shifting away from Uptravi.

    By Margaret Patrick
  • uploads///man _
    Company & Industry Overviews

    What’s Been Dragging Down CymaBay Therapeutics Stock

    CymaBay Therapeutics (CBAY) closed at $6.17 on June 12, 1.98% higher than its previous close, 28.01% above its 52-week low of $4.82, and 58.87% below its 52-week high of $15.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Biogen Pursuing Investigational Candidates in Alzheimer’s Disease

    Biogen (BIIB) has entered into a licensing agreement with Bristol-Myers Squibb (BMY) for exclusive global rights for the development and commercialization of BMS-986168.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    This Space Presents a Market Opportunity for Valeant

    In Valeant’s 2Q16 earnings, Xifaxan reported a year-over-year (or YoY) increase in monthly prescriptions of about 28.0%.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Amgen’s Nephrology Drugs Expect Falling Revenue in 4Q15

    Analysts projected a fall in the revenue for Amgen’s nephrology drugs, Aranesp and Epogen, in 4Q15. The drugs are expected to suffer in the coming quarters.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders

    Ligand Pharmaceuticals has developed a product portfolio that spans more than 700 patents offering varying degrees of protection to the assets.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva Is Expected to See a Fall in Its Profit Margins in 2017

    Teva Pharmaceutical (TEVA) expects its 2017 non-generally accepted accounting principles (non-GAAP) earnings per share (or EPS) to fall in the range of $4.9–$5.3.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Is Focusing on These Strategic Areas in 2016

    With 642 million people expected to suffer from diabetes globally by 2040, the disease is expected to offer multiple growth opportunities for Novo Nordisk.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca’s New Oncology Portfolio May See Healthy Growth

    In 1Q17, AstraZeneca’s (AZN) new oncology portfolio reported global sales of around $236.0 million. Tagrisso earned revenues of $171.0 million globally.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Gilead Sciences’ Product Line Extension

    As part of its significant product line extension, Gilead Sciences (GILD) is entering therapeutic areas such as oncology, pulmonology, and cardiology.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Abiomed’s Profit Margin Expectations for Fiscal 2018

    For fiscal 2018 (ended March 31, 2018), Abiomed (ABMD) has projected that its operating margins will be in the range of 22%–24%.

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    CBD: Japan Welcomes NBEV, Stock Pops

    Today, New Age Beverages Corporation (NBEV) announced that it would launch its CBD (cannabidiol) based products. Share prices jumped by 14.96% to $3.20.

    By Margaret Patrick
  • uploads///pulse trace _
    Company & Industry Overviews

    Analyst Ratings for Endo International and Peers in August

    In the second quarter, Endo International (ENDP) reported revenues of $715 million, which is a YoY decline of 18.4%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals: Developing Therapies for Hereditary ATTR Amyloidosis

    Alnylam Pharmaceuticals (ALNY) is currently developing three investigational therapies—Patisiran, Revusiran, and ALN-TTRsc02—for the treatment of patients with hereditary ATTR amyloidosis.

    By Margaret Patrick
  • uploads///CVX H
    Company & Industry Overviews

    Major Events That Affected Chevron and Shell in 3Q17

    Chevron’s 1H17 results improved from ~-$2.2 billion in 1H16 to $4.1 billion due to an across-the-board rise in its segmental earnings.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Amgen: Exploring Opportunities in the Bone Segment

    Amgen’s Prolia is the leading brand for treating postmenopausal osteoporosis, or PMO, in women with a high risk of bone fracture.

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    Canopy Growth: A Cannabis 2.0 Update

    On December 6, Canopy Growth (CGC) disclosed its rollout plans for Cannabis 2.0 products, such as chocolates, vape pens, vape cartridges, and beverages.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Hopes to Commercialize Next-Generation HCV Regimen by 2017

    AbbVie (ABBV) plans to complete its Phase 3 registrational program for investigational next-generation Hepatitis C virus (or HCV) therapy by 2016.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    What Do Analysts Recommend for United Therapeutics?

    23.1% of analysts gave United Therapeutics (UTHR) a “buy” recommendation while 69.2% of analysts rated the company a “hold.”

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Which Hospital Stocks Are Expected to Benefit Most?

    Trumpcare’s failure is considered to be a boon by hospital companies treating a significant portion of Medicaid members.

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    Valuation for Cannabis Stocks in October

    The cannabis industry is fighting against the ongoing US-China trade war and recessionary worries, which have hurt valuations across the global market.

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    Will Santa Claus Rally Boost Cannabis Stocks?

    On December 26, a Santa Claus rally seems to be in full swing. This effect pushed the S&P 500 (SPX) and Nasdaq Composite Index (COMP) to record highs.

    By Margaret Patrick
  • uploads///AdobeStock_
    Materials

    What to Expect from IIPR’s Earnings for Q3

    Innovative Industrial Properties (IIPR) is scheduled to release its Q3 earnings results on November 6. Find out what cannabis investors can expect.

    By Margaret Patrick
  • uploads///pills medical money
    Company & Industry Overviews

    Why Pfizer’s Share Price Fell on November 20

    On November 20, Pfizer (PFE) closed at $43.53, which was 1.47% lower than its previous closing price.

    By Margaret Patrick
  • uploads///event _
    Cannabis

    Medical Cannabis: A Hot Topic at Events Across the World

    These days, experts are discussing the pros and cons of medical cannabis at multiple conferences and summits around the world.

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    Why Trump Has Banned Flavored e-Cigarettes

    On January 2, as reported by CNBC, the FDA banned most fruit- and mint-flavored nicotine products. The move aims to reduce teen usage of these products.

    By Margaret Patrick
  • uploads///get budding BuBSErSL_M unsplash
    Cannabis

    Why Marijuana Revenues in Colorado Keep Rising

    Colorado reported $1.16 billion in marijuana sales in the first eight months of 2019. In 2018, the state reported marijuana sales of $1.54 billion.

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    New York: Curaleaf Launched Cannabis Flower Products

    On Monday, Curaleaf (CURA) (CURLF) became the first company to launch medical cannabis flower products in New York. The state offers growth opportunities.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Biogen Trades at High Valuation Multiples Due to Strong Research Pipeline

    After the release of its 3Q15 earnings results on October 21, Biogen was trading at PE multiples in the range of 13.8x–15.3x.

    By Margaret Patrick
  • uploads///Graph
    Macroeconomic Analysis

    What do falling oil prices mean for the hospital industry?

    Economic conditions like falling oil prices affect the healthcare industry with a lag. This makes the hospital industry a good investment option.

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    What Legalizing Cannabis Means for Mexico

    Mexico is fast approaching its October 23 marijuana legalization deadline. Multiple legalization proposals before parliament are creating confusion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Durvalumab and Tagrisso May Boost AstraZeneca’s Revenues in 2017

    On December 9, 2016, the FDA accepted for review its first-ever biologics license application (or BLA) submitted by AstraZeneca (AZN).

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    Was CGC a Big Mistake for Constellation Brands?

    Canopy Growth (CGC) has seen dizzying ups and gloomy downs in 2019. The stock jumped up by 79.91% from $28.92 on January 2 to $52.03 on April 29.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Merck’s Key Growth Drivers for 2019?

    Merck & Co. (MRK) highlighted its oncology, vaccines, hospital and specialty care, and animal health businesses as its key growth drivers in 2018.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Factors That Will Determine Repatha’s Future Commercial Success

    Amgen (AMGN) believes that Repatha will be widely accepted as a major cardiovascular therapy for high-risk patients.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Continues to Be a Leader in the Global Insulin Market

    Accounting for a ~46% market share, Novo Nordisk (NVO) is expected to continue to benefit from the positive trends in the global insulin market

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novartis Focuses on Portfolio Prioritization to Boost Profitability

    To ensure long-term relevance as well as quick adaptability to changing market needs, Novartis (NVS) is focusing on five major initiatives in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Opdivo Is a Key Growth Driver for Bristol-Myers Squibb in 2016

    On November 10, 2016, the FDA approved Opdivo as a treatment option for patients suffering with recurring or metastatic squamous cell carcinoma of the head and neck (or SCCHN).

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    The High Hope of Exelixis’s Cabometyx Label Expansion

    Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Behind Celgene’s Blockbuster Revenue Hit in 4Q16

    In 2016, Celgene’s (CELG) Otezla attained blockbuster status by earning revenues in excess of $1 billion as a therapy for psoriasis and psoriatic arthritis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Strengthens Its Position in the Virology Segment

    In addition to Humira, AbbVie also offers several virology drugs targeting diseases such as hepatitis C, HIV, and respiratory syncytial virus.

    By Margaret Patrick
  • uploads///blood _
    Company & Industry Overviews

    Analysts’ Recommendations for Haemonetics and Peers in March 2018

    In its fiscal 3Q18, which ended on December 31, 2017, Haemonetics (HAE) reported revenue of close to $234 million.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Entering Migraine Market Won’t Be Easy for Novartis, Amgen

    Novartis (NVS) and Amgen (AMGN) recently announced that the CGRP inhibitor therapy, AMG 334, reported positive results in a Phase 2 clinical trial as a therapy for preventing chronic migraine.

    By Margaret Patrick
  • uploads///CGC
    Cannabis

    CGC: How the Future Looks Under Its New CEO

    On December 9, Canopy Growth (CGC) appointed David Klein as its new CEO effective January 14. He’s the current CFO of Constellation Brands.

    By Margaret Patrick
  • uploads///Graph
    Macroeconomic Analysis

    Must-read: Is the US hospital industry truly non-cyclical?

    The hospital sector is widely considered a non-cyclical or defensive industry, meaning demand for hospital services doesn’t change with the economic cycle.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Will Be a Key Driver of Biogen’s Future Valuations?

    Biogen’s investigational Alzheimer’s disease drug, aducanumab, is one of the four therapies accepted in the EMA’s Priority Medicines program (or PRIME).

    By Margaret Patrick
  • uploads///tim trad UevKKQQI unsplash
    Cannabis

    Medical Marijuana Faces Setback in Ohio

    The State Medical Board of Ohio refused to include anxiety disorders and autism in Ohio’s Medical Marijuana Control Program. Will the market suffer?

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva’s Share of the US Generics Market Could Boost Its Stock

    Teva Pharmaceutical Industries accounts for 18% of the US generic drug market. This share is significantly higher than those of Mylan, Novartis, and Pfizer.

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    Is Charlotte’s Web Holdings a Good Buy This Month?

    Charlotte’s Web Holdings (CWEB) (CWBHF) stock is currently down 23.64% year-to-date on US over-the-counter exchanges. What’s affected investor sentiment?

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Medicaid Restrictions Are Affecting Gilead’s Hepatitis C Drug Sales

    Since the launch of Sovaldi in late 2013, Gilead Sciences has managed to treat about 1,000,000 hepatitis C (or HCV) patients globally.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca May Witness a Fall in 2017 Net Profit Margin

    Wall Street analysts have projected AstraZeneca’s (AZN) 2017 net profit margins at about 12.2%, which is lower by 300 basis points on a YoY basis.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Universal Health Services’ Net Profit Margin Expected to Rise

    Wall Street analysts expect that Universal Health Services (UHS) will report higher net profit margins in 3Q15 compared to margins in 3Q14.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Tagrisso Expected to Be a Key Growth Driver for AstraZeneca in 2017

    Launched in Japan in 2Q16, AstraZeneca’s (AZN) 1Q17 revenues for Tagrisso approached $39 million in this major emerging market.

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    Cannabis Stocks: What Happens in a Recession?

    As market analysts increasingly predict an upcoming global recession, we take a look at the impact of a recession on cannabis stocks.

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    What’s the Market Potential for CBD?

    The FDA has issued warning letters to 15 companies involved in illegal sales of non-psychoactive CBD products. What’s the legal market’s potential?

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Dupixent May Be Strong Growth Driver for Sanofi in the Future

    Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.